Pazopanib for the treatment of renal cancer.

@article{AlMarrawi2011PazopanibFT,
  title={Pazopanib for the treatment of renal cancer.},
  author={Mhd Yaser Al-Marrawi and Brian I. Rini},
  journal={Expert opinion on pharmacotherapy},
  year={2011},
  volume={12 7},
  pages={
          1171-89
        }
}
INTRODUCTION Dramatic advances in the care of patients with advanced renal cell carcinoma (RCC) have occurred over the last 10 years. Insights into the molecular pathogenesis of this disease have elucidated the importance of signaling cascades related to angiogenesis in the management of RCC. Pazopanib is a novel, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3; platelet-derived growth factor receptors (PDGFR)-α and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie • 2017
View 1 Excerpt

Triggering of Suicidal Erythrocyte Death by Pazopanib.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology • 2016